DB
PTX

Dmitry Balyasny’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Dmitry Balyasny’s Portfolio PTX Stock Details PTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,170
Closed -$5K – 1452
2016
Q2 		$5K Buy
+1,170
New +$7.64K ﹤0.01% 1127
2015
Q4 		– Sell
-3,680
Closed -$116K – 1609
2015
Q3 		$116K Buy
+3,680
New +$176K ﹤0.01% 1062

Other funds holding PTX

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $783M AUM 81.58% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Dmitry Balyasny's PTX Position: Q3 2016 in Review

Dmitry Balyasny sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q3 2016, closing a stake of 1,170 shares — an estimated $5K sold.

Dmitry Balyasny first reported a position in PTX in Q3 2015 and held it in 2 quarters. The position peaked at $116K in Q3 2015. 48 funds tracked by Wall St. Rank hold PTX as of Q3 2016.

  • Dmitry Balyasny reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q3 2016 after selling out during the quarter.
  • Dmitry Balyasny sold 1,170 Pernix Therapeutics Holdings, Inc. shares in Q3 2016, an estimated $5K.
  • Dmitry Balyasny first reported a position in Pernix Therapeutics Holdings, Inc. in Q3 2015 and held it in 2 quarters.
  • Dmitry Balyasny's Pernix Therapeutics Holdings, Inc. position peaked at $116K in Q3 2015.
  • 48 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q3 2016.

Based on Balyasny Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.